Financial Statements/ESG Information - [Interim/Half-Year Report]

Keymed Biosciences Inc. operates a biotechnology company. The Company focus on the in-house discovery and development of innovative biological therapies. Keymed Biosciences provides services in China.

2025 Interim Report

Announcements and Notices - [Interim Results / Change in Directors or of Important Executive Functions or Responsibilities / Change in Company Secretary]

Interim Results Announcement For The Six Months Ended June 30, 2025; And Resignation Of Chief Financial Officer And
Joint Company Secretary

Announcements and Notices - [Date of Board Meeting]

Date Of Board Meeting

Announcements and Notices - [Results of AGM]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Keymed Biosciences (2162 HK)

2025 Interim Report

Interim Results Announcement For The Six Months Ended June 30, 2025; And Resignation Of Chief Financial Officer And Joint Company Secretary

Date Of Board Meeting

Poll Results Of The Annual General Meeting Held On June 26, 2025

Next Day Disclosure Return

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)